固定剂量四因子血栓复合缩剂用于逆转抗凝血:有效性,安全性和成本节省的评估
Amer Al Homssi1, Ryan Lokkesmoe2, Ryan Powers1
1Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Journal of hematology
|September 4, 2025
概括
在华法林和DOAC逆转方面,固定剂量的四因子前激素复合缩物 (4F-PCC) 提供了显著的成本节约. 这种方法的安全性和有效性与传统的剂量方法相美.
科学领域:
- 药理学和治疗学
- 血液学
- 健康经济学
背景情况:
- 四因子血栓复合缩剂 (4F-PCC) 用于治疗直接口服抗凝剂 (DOAC) 患者的华法林逆转和非标签治疗出血.
- 优化4F-PCC剂量策略的有效性和成本效益,如固定的剂量,仍然是一个正在进行的研究领域.
研究的目的:
- 追溯评估与固定的4F-PCC剂量相关的疗效,安全性和成本节约.
- 将固定的剂量方案 (华法林1,500 IU,DOACs2,000 IU) 与传统的基于体重和INR的剂量进行比较.
主要方法:
- 从2018年10月到2021年4月的三家医院患者记录的回顾性审查.
- 分析包括592名接受固定剂量4F- PCC治疗的华法林逆转 (n=414) 或DOAC治疗 (n=127) 的患者.
- 评估结果:30天出血/血栓事件,重复剂量要求,全因死亡率和成本节省.
主要成果:
- 在接受华法林治疗的89%患者中,国际正常化比率 (INR) 低于2.
- 在这两组中,不到5%的患者需要重复服用4F-PCC.
- 报告每名患者的显著中位成本节省:华法林1567美元,DOACs3936美元,每年医院节省大量.
结论:
- 固定的4F-PCC剂量是调整剂量的经济有效替代方案.
- 固定的剂量策略表明血栓形成和死亡率与现有研究相似.
- 这种方法为医疗保健系统提供了显著的经济效益,而不会损害患者的安全或疗效.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Anticoagulant Drugs: Low-Molecular-Weight Heparins
888
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
888
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
642
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
642
Venous Thrombosis IV: Nursing Management
22
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
22
Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K


